Jolanda Howe Sells 658 Shares of Mirum Pharmaceuticals (NASDAQ:MIRM) Stock

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) SVP Jolanda Howe sold 658 shares of the business’s stock in a transaction dated Wednesday, September 2nd. The stock was sold at an average price of $100.00, for a total transaction of $65,800.00. Following the completion of the sale, the senior vice president directly owned 616 shares of the company’s stock, valued at $61,600. The trade was a 51.65% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Jolanda Howe also recently made the following trade(s):

• On Tuesday, August 18th, Jolanda Howe sold 40,000 shares of Mirum Pharmaceuticals stock. The stock was sold at an average price of $100.00, for a total transaction of $4,000,000.00.
• On Monday, August 3rd, Jolanda Howe sold 1,840 shares of Mirum Pharmaceuticals stock. The stock was sold at an average price of $105.29, for a total value of $193,733.60.
• On Wednesday, July 1st, Jolanda Howe sold 2,721 shares of Mirum Pharmaceuticals stock. The stock was sold at an average price of $120.00, for a total transaction of $326,520.00.
• On Wednesday, June 17th, Jolanda Howe sold 2,594 shares of Mirum Pharmaceuticals stock. The shares were sold at an average price of $101.95, for a total transaction of $264,458.30.

Mirum Pharmaceuticals Stock Up 0.3%

NASDAQ:MIRM opened at $100.90 on Friday. The company has a current ratio of 2.86, a quick ratio of 2.74 and a debt-to-equity ratio of 1.28. The stock has a 50 day moving average of $109.09 and a 200-day moving average of $101.73. The firm has a market capitalization of $6.55 billion, a PE ratio of -6.93 and a beta of 0.49. Mirum Pharmaceuticals, Inc. has a 52 week low of $63.23 and a 52 week high of $130.00.

Mirum Pharmaceuticals (NASDAQ:MIRM) last released its quarterly earnings data on Wednesday, August 5th. The company reported ($1.06) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.74) by ($0.32). Mirum Pharmaceuticals had a negative return on equity of 36.28% and a negative net margin of 139.18%.The firm had revenue of $176.24 million during the quarter, compared to analyst estimates of $166.33 million. During the same period last year, the business earned ($0.12) EPS. The firm’s revenue was up 37.9% on a year-over-year basis. Analysts predict that Mirum Pharmaceuticals, Inc. will post -1.31 EPS for the current year.

Institutional Trading of Mirum Pharmaceuticals

A number of hedge funds have recently bought and sold shares of the company. Comerica Bank raised its holdings in shares of Mirum Pharmaceuticals by 45.1% during the first quarter. Comerica Bank now owns 895 shares of the company’s stock valued at $40,000 after acquiring an additional 278 shares during the period. AQR Capital Management LLC boosted its stake in Mirum Pharmaceuticals by 307.3% in the 1st quarter. AQR Capital Management LLC now owns 49,076 shares of the company’s stock worth $2,211,000 after purchasing an additional 37,028 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in Mirum Pharmaceuticals by 7.1% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 26,047 shares of the company’s stock worth $1,176,000 after purchasing an additional 1,720 shares during the period. Caxton Associates LLP purchased a new position in Mirum Pharmaceuticals during the 1st quarter worth approximately $217,000. Finally, Empowered Funds LLC grew its position in Mirum Pharmaceuticals by 15.4% during the 1st quarter. Empowered Funds LLC now owns 38,386 shares of the company’s stock worth $1,729,000 after purchasing an additional 5,120 shares in the last quarter.

Analysts Set New Price Targets

MIRM has been the subject of several research analyst reports. TD Cowen cut their price objective on Mirum Pharmaceuticals from $145.00 to $140.00 and set a “buy” rating for the company in a report on Thursday, August 6th. Citigroup reiterated a “market outperform” rating on shares of Mirum Pharmaceuticals in a research report on Thursday, August 27th. HC Wainwright cut their price target on shares of Mirum Pharmaceuticals from $185.00 to $140.00 and set a “buy” rating for the company in a report on Thursday, August 6th. Morgan Stanley set a $137.00 price objective on shares of Mirum Pharmaceuticals in a research report on Thursday, August 6th. Finally, Weiss Ratings raised shares of Mirum Pharmaceuticals from a “sell (d-)” rating to a “sell (d)” rating in a research note on Thursday, August 6th. One analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $137.31.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.